BRCA1 and ovarian carcinoma: These agents demonstrate synthetic lethality with inherent or induced defects in homologous recombination repair (HR), such as loss of Breast Cancer 1 and 2 (BRCA1/2) protein function, and have recently been approved for use in advanced ovarian cancers with a “BRCAness” phenotype.